Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220046 · ClinicalTrials.gov registry record · Phase 1
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
A Phase 1 study of Pancreas Cancer and Gastrointestinal Cancer, sponsored by University of Nebraska.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT05220046 is a Phase 1 study of Pancreas Cancer and Gastrointestinal Cancer that is active but no longer recruiting, run by University of Nebraska. The registered enrollment target is 24 participants, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05220046, a Phase 1 study of Pancreas Cancer and Gastrointestinal Cancer, is active but no longer recruiting, sponsored by University of Nebraska.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or inoperable gastrointestinal cancers. Secondary objectives include pre/post, and longitudinal measurement of distress in intervention participants and a paired family member who is in an observational arm.
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (1)
Nebraska
- University of Nebraska Medical Center - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220046
The ClinicalTrials.gov registry entry for NCT05220046 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 907-participant average among 54 other Pancreas Cancer trials with a reported enrollment target (97% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreas Cancer appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05220046 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT05220046 about?
NCT05220046 is a clinical study titled "Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers". The primary objective of this study is to evaluate the ability to recruit and retain participants, and to successfully conduct a psilocybin-based protocol, for a study of the treatment of distress related to stage IV or inoperable gastrointestinal cancers. Secondary objectives include pre/post, and ...
What is the current status of trial NCT05220046?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2023-04-10. Estimated completion is 2026-05.
What conditions does trial NCT05220046 study?
This clinical trial studies the following conditions: Pancreas Cancer, Gastrointestinal Cancer, Biliary Tract Cancer, Psychological Distress.
What interventions are being tested in trial NCT05220046?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05220046?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05220046 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreas Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
RECRUITING · Phase 1
-
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.